Skip to main navigation

Main Menu

About
Our Approach
Pipeline
- Publications
Therapeutic Focus
Careers
- Current Openings
- Faces of Fulcrum
Investor Relations
Contact

News Releases

News Releases

Year

Nov 17, 2021

Fulcrum Therapeutics® Appoints Sonja L. Banks to its Board of Directors

Nov 04, 2021

Fulcrum Therapeutics® Reports Recent Business Highlights and Third Quarter 2021 Financial Results

Nov 03, 2021

Fulcrum Therapeutics™ to Participate in Upcoming November Investor Conferences

Oct 28, 2021

Fulcrum Therapeutics™ to Host Third Quarter 2021 Financial Results Conference Call and Webcast on Thursday, November 4, 2021 at 8:00 a.m. ET

Oct 01, 2021

Fulcrum Therapeutics™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Sep 20, 2021

Fulcrum Therapeutics™ Announces Multiple Presentations During the Virtual Congress of the World Muscle Society

Sep 10, 2021

Fulcrum Therapeutics™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Sep 08, 2021

Fulcrum Therapeutics™ Appoints Mel Hayes as Chief Commercial Officer

Sep 02, 2021

Fulcrum Therapeutics™ to Participate in Upcoming Investor Conferences

Aug 16, 2021

Fulcrum Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

Pagination

Current page 1
Page 2
Page 3
Page 4
Next page
Last page

Displaying 1 - 10 of 35

Investor Tools

Privacy Policy | EU Privacy Policy | Terms of use

Social Media Guidelines

Main Menu

About
Our Approach
Pipeline
- Publications
Therapeutic Focus
Careers
- Current Openings
- Faces of Fulcrum
Investor Relations
Contact